Sugi Predict

Sugi Predict / Compounds / SCHEMBL29638078

SCHEMBL29638078

SCHEMBL29638078

CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 2/20 0.57
▸ F2 P00734 4/20 0.54
▸ KDM1A O60341 2/20 0.53
▸ MC4R P32245 1/20 0.53
▸ NPY1R P25929 1/20 0.51
▸ NPY2R P49146 1/20 0.51
▸ NPY4R P50391 1/20 0.51
▸ NPY5R Q15761 1/20 0.51
▸ GHSR Q92847 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4807604 0.94 APLNR (0.56) APLNRMC4R
SCHEMBL4807584 0.94 APLNR (0.56) APLNRMC4R
SCHEMBL4804770 0.89 APLNR (0.55) APLNRF2
SCHEMBL4804787 0.89 APLNR (0.55) APLNRF2
SCHEMBL30431287 0.89 MC4R (0.57) APLNRF2MC4RNPY1RNPY2R
SCHEMBL30646310 0.87 APLNR (0.56) APLNRF2KDM1AGHSR
SCHEMBL29416132 0.87 APLNR (0.56) APLNRF2KDM1AGHSR
SCHEMBL30277111 0.87 CTSL (0.56) APLNRF2
SCHEMBL4301705 0.87 MC4R (0.52) APLNRKDM1AMC4R
SCHEMBL31186830 0.86 F2 (0.57) APLNRF2MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4591934-A2 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2025-07-30 — — EP disclosed
EP-4523749-A2 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2025-03-19 — — EP disclosed
US-12214015-B2 Use of c-type natriuretic peptide variants to treat osteoarthritis BIOMARIN PHARMACEUTICAL INC. (US) 2025-02-04 — — US disclosed
EP-4029512-A1 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2022-07-20 — — EP disclosed
EP-4019038-A2 USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS BioMarin Pharmaceutical Inc. (US) 2022-06-29 — — EP disclosed
US-20220160836-A1 USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS BIOMARIN PHARMACEUTICAL INC. 2022-05-26 — — US disclosed
Send feedback